Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients

Danielle Daitch, Jonathan Daitch, Daniel Novinson, Michael Frey, Carol Mitnick, Joseph Pergolizzi

Research output: Contribution to journalArticle

Abstract

Objective: This study aims to determine the effectiveness of converting patients from high doses of full-opioid agonists to sublingual (SL) buprenorphine. Design: An observational report of outcomes assessment. Setting: An interventional pain management practice setting in the United States. Subjects: Thirty-five chronic pain patients (age 24-66) were previously treated with high-dose opioid-agonist drugs and converted to SL buprenorphine. Patients' daily morphine equivalents ranged from 200mg to 1,370mg preconversion, with a mean daily dose of 550mg. Methods: A retrospective chart analysis examined numerical pain levels and quality of life scores before and 2 months after conversion to SL buprenorphine. Results: After continuation of SL buprenorphine therapy for 2 months, the mean pain score decreased from 7.2 to 3.5 (P

Original languageEnglish (US)
Pages (from-to)2087-2094
Number of pages8
JournalPain Medicine
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Buprenorphine
Chronic Pain
Opioid Analgesics
Quality of Life
Pain
Pain Management
Morphine
Outcome Assessment (Health Care)
Pharmaceutical Preparations
Therapeutics

Keywords

  • Analgesia
  • Buprenorphine
  • Opioid conversion
  • Opioid tolerance
  • Opioid-iNDUCED hYperalgesia
  • Sublingual buprenorphine

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. / Daitch, Danielle; Daitch, Jonathan; Novinson, Daniel; Frey, Michael; Mitnick, Carol; Pergolizzi, Joseph.

In: Pain Medicine, Vol. 15, No. 12, 01.12.2014, p. 2087-2094.

Research output: Contribution to journalArticle

Daitch, Danielle ; Daitch, Jonathan ; Novinson, Daniel ; Frey, Michael ; Mitnick, Carol ; Pergolizzi, Joseph. / Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. In: Pain Medicine. 2014 ; Vol. 15, No. 12. pp. 2087-2094.
@article{abdae010e1294b778167364f343b343b,
title = "Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients",
abstract = "Objective: This study aims to determine the effectiveness of converting patients from high doses of full-opioid agonists to sublingual (SL) buprenorphine. Design: An observational report of outcomes assessment. Setting: An interventional pain management practice setting in the United States. Subjects: Thirty-five chronic pain patients (age 24-66) were previously treated with high-dose opioid-agonist drugs and converted to SL buprenorphine. Patients' daily morphine equivalents ranged from 200mg to 1,370mg preconversion, with a mean daily dose of 550mg. Methods: A retrospective chart analysis examined numerical pain levels and quality of life scores before and 2 months after conversion to SL buprenorphine. Results: After continuation of SL buprenorphine therapy for 2 months, the mean pain score decreased from 7.2 to 3.5 (P",
keywords = "Analgesia, Buprenorphine, Opioid conversion, Opioid tolerance, Opioid-iNDUCED hYperalgesia, Sublingual buprenorphine",
author = "Danielle Daitch and Jonathan Daitch and Daniel Novinson and Michael Frey and Carol Mitnick and Joseph Pergolizzi",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/pme.12520",
language = "English (US)",
volume = "15",
pages = "2087--2094",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients

AU - Daitch, Danielle

AU - Daitch, Jonathan

AU - Novinson, Daniel

AU - Frey, Michael

AU - Mitnick, Carol

AU - Pergolizzi, Joseph

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective: This study aims to determine the effectiveness of converting patients from high doses of full-opioid agonists to sublingual (SL) buprenorphine. Design: An observational report of outcomes assessment. Setting: An interventional pain management practice setting in the United States. Subjects: Thirty-five chronic pain patients (age 24-66) were previously treated with high-dose opioid-agonist drugs and converted to SL buprenorphine. Patients' daily morphine equivalents ranged from 200mg to 1,370mg preconversion, with a mean daily dose of 550mg. Methods: A retrospective chart analysis examined numerical pain levels and quality of life scores before and 2 months after conversion to SL buprenorphine. Results: After continuation of SL buprenorphine therapy for 2 months, the mean pain score decreased from 7.2 to 3.5 (P

AB - Objective: This study aims to determine the effectiveness of converting patients from high doses of full-opioid agonists to sublingual (SL) buprenorphine. Design: An observational report of outcomes assessment. Setting: An interventional pain management practice setting in the United States. Subjects: Thirty-five chronic pain patients (age 24-66) were previously treated with high-dose opioid-agonist drugs and converted to SL buprenorphine. Patients' daily morphine equivalents ranged from 200mg to 1,370mg preconversion, with a mean daily dose of 550mg. Methods: A retrospective chart analysis examined numerical pain levels and quality of life scores before and 2 months after conversion to SL buprenorphine. Results: After continuation of SL buprenorphine therapy for 2 months, the mean pain score decreased from 7.2 to 3.5 (P

KW - Analgesia

KW - Buprenorphine

KW - Opioid conversion

KW - Opioid tolerance

KW - Opioid-iNDUCED hYperalgesia

KW - Sublingual buprenorphine

UR - http://www.scopus.com/inward/record.url?scp=84919685075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919685075&partnerID=8YFLogxK

U2 - 10.1111/pme.12520

DO - 10.1111/pme.12520

M3 - Article

C2 - 25220043

AN - SCOPUS:84919685075

VL - 15

SP - 2087

EP - 2094

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 12

ER -